Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

  • Abdul Hakim Alkatiri Department of Cardiology and Vascular Medicine, Faculty of Medicine, Univ. Hasanuddin
  • Yoga Yuniadi Department of Cardiology and Vascular Medicine, Faculty of Medicine, Univ. of Indonesia and National Cardiovascular Center Harapan Kita
  • Dicky A Hanafy Department of Cardiology and Vascular Medicine, Faculty of Medicine, Univ. of Indonesia and National Cardiovascular Center Harapan Kita
  • Doni Firman Department of Cardiology and Vascular Medicine, Faculty of Medicine, Univ. of Indonesia and National Cardiovascular Center Harapan Kita
  • Sunarya Soerianata Department of Cardiology and Vascular Medicine, Faculty of Medicine, Univ. of Indonesia and National Cardiovascular Center Harapan Kita

Abstract

Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of < 90 minutes will improved TIMI grade flow of infarct related coronary artery (IRA). However, significant numbers of patient arrived in emergency room/PCI center with pain awitan of > 3 hours. This study was aimed to evaluated effect of eptifibatide administra-tion timing to TIMI grading flow in first angiographic IRA during primary PCI in patients with STEMI.
Methods and result. Of 116 consecutive STEMI patients who underwent primary PCI, 79 patients received ebtifibatide < 90 minutes (Group 1) and 37 patients received eptifibatide > 90 minutes (Group 2) before first angiographic of IRA. There were no significant differences of TIMI 3 flow proportion after PCI between the groups (86.1% vs 83.8% for Group 1 and 2 respectively, p = 0.745). Group 2 showed more frequent TIMI 2 flow (18.9% vs 5.1%, p = 0.036) but tend to have less frequent TIMI 0 flow (56.8 % vs 67.1%, p = 0.281).
Conclusion. Patients who received eptifibatide > 90 minutes before first angiographic IRA during primary PCI achieved more appropriate TIMI flow as compare to that received eptifibatide < 90 minutes.

Downloads

Download data is not yet available.

References

Mahmud E, Pajeshki B.,Salami A., Keramati S., Highlights 2004 Transcatheter Cardiovascular Therapeutics (CTC) Annual Meeting Clinical Implication. J Am Coll Cardiol. 2005;45:796-2.

Montalescot G, Baragan P, Wittenberg O, et al. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long term follow up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.

Gibson CM, Kirtane AJ, Murphy SA, et al. Early initiation of ebtifibatide in the emergency department before primary percutaneous coronary intervention for ST segment elevation myocardial infarction : Result of the Time to Intergrillin Therapy in Acute Myocardial infarction (TITAN)-TIMI 34 trial. Am Heart J. 2006;152:668-675.

Gabriel HM, Oliveira JA, da Silva PC, et al. Early administra-tion of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Result of the early ReoPro administration in myo-cardial infarction (ERAMI) trial. Catheter Cardiovasc Interv. 2006;68:218-224.

Ellis SG, Tandera M, de Belder MA, et al. facilitated PCI in patients with ST elevation myocardial infarction. N Engl J Med. 2008;358:2205-2217.

Aquilina M, Varani E, Balducelli M, et al. Administration of ebtifibatide during transfer for primary PCI in patients with STEMI: Effect on Pre-PCI TIMI. J Invasive Cardiol. 2009;21:115-120.

Montalescot G, Borentain M, Payot L, et al. Early vs late ad-ministration of glycoprotein IIb/IIIa Inhibitor in primary per-cutaneous coronary intervention of acute ST-segment elevation myocardial infarction A meta-analysis. JAMA. 2004;292:362-366.

Zeymer Uwe, Zahn R, Schiele R, et al. Early eptifibatide im-proves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrillin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;26:1971-1977.

De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitor in primary angioplasty (EGYPT) cooperation : an indi-vidual patient data meta-analysis. Heart. 2008;94:1548-1558.

Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA guideline for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guideline on percutaneous coronary intervention (updating the 2005 diovascular Intervention 2009).
Views & Downloads
Abstract views: 860   
PDF (Bahasa Indonesia) downloads: 698   
How to Cite
Alkatiri, A., Yuniadi, Y., Hanafy, D., Firman, D., & Soerianata, S. (1). Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI. Indonesian Journal of Cardiology, 32(1), 27-33. https://doi.org/10.30701/ijc.v32i1.118
Section
Clinical Research